Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 9:39 PM
Ignite Modification Date: 2025-12-25 @ 7:22 PM
NCT ID: NCT00672932
Description: 6 subjects who rolled over to treatment after 12 weeks of no treatment were followed for an additional 12 weeks. 1 subject in the Raltegravir group was not included in other analyses because a pharmacological study showed no drug in either plasma or CSF.
Frequency Threshold: 5
Time Frame: 12 weeks
Study: NCT00672932
Study Brief: Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Raltegravir Group The raltegravir dosing will be 400mg twice daily by mouth. Subjects will continue all of their regular medications throughout the protocol. None None 0 15 0 15 View
No Augmented Treatment Subjects randomized not to receive augmented treatment will continue in the study with their regular antiretroviral regimen. None None 0 9 0 9 View
Serious Events(If Any):
Other Events(If Any):